Indoco Remedies is a pharmaceutical company that makes and sells both branded prescription medicines and the active ingredients inside them, operating across more than 55 countries from a manufacturing base of 11 plants in India. It began in 1947 when its founder, an importer of European drugs, was forced by a newly independent India’s ban on imports to start manufacturing instead-a pivot from trading to making that still defines the company’s fully integrated approach. The recurring pattern is a deep investment in difficult-to-make products-sterile injectables, complex ophthalmics, and niche generics-and then selling them through a multi-layered network: a domestic field force that calls on over 2,40,000 doctors, partnerships with large generic companies abroad, and a growing over-the-counter oral care brand built on the back of its ethical prescription heritage.
Business segments
A single integrated pharmaceutical engine with three customer-facing channels-domestic branded prescriptions, international generics, and a small over-the-counter oral care business-all fed by the same manufacturing and R&D backbone.
1. Domestic branded formulations: the prescription engine that funds everything else
A field force of over 2,300 medical representatives generates more than 10 crore prescriptions a year from over 2,40,000 doctors, making Indoco the 20th most prescribed company in India.
- Prescriptions, not just sales - the business is built on a “brand-distribution-doctor” model where medical representatives call on doctors across 10 specialised marketing divisions, generating prescriptions that flow through 2,800 stockists and 25 carrying-and-forwarding agents to reach patients.
- Chronic shift underway - historically dependent on acute therapies like anti-infectives and respiratory drugs, the company is deliberately tilting toward sub-chronic and chronic areas; acute now accounts for 46% of domestic revenue, down from a larger share, while sub-chronic and chronic together make up 53%.
- Brands that hold top ranks - Cyclopam, its largest brand, crossed ₹1,000 million in sales, and Rexidin-M Forte gel became the most prescribed stomatological brand in India as of early 2026; across the portfolio, over 43 products rank in the top five of their sub-segments.
- Geographically balanced - no single region dominates: the South contributes roughly a third of domestic revenue, the West just under a third, and the East and North together the remaining third, with Kashmir newly added to the marketing map.
- New therapy entries - in FY25 the company entered dermatology and anti-glaucoma, two high-potential segments, and launched 13 new products domestically; new introductions now contribute 6% of the top line.
2. International generics: difficult-to-make products for regulated and emerging markets
The international business supplies finished dosage forms to over 55 countries, with a deliberate focus on sterile injectables and ophthalmics where manufacturing complexity keeps price pressure lower.
- Sterile niche as a shield - a large part of US sales comes from injectables and ophthalmics, products that are hard to develop and manufacture, so they face fewer shortages-driven price swings than solid oral generics.
- Partner-led go-to-market - Indoco does not have its own front end abroad; instead it licenses dossiers, contract-manufactures for large pharma companies, and shares costs and profits with big generic partners, including Teva for Brinzolamide ophthalmic suspension and Perrigo for paracetamol in the UK.
- Dominant positions in narrow markets - with partners, Indoco holds over 60% of the UK paracetamol market and over 80% of the German allopurinol market; in Germany it won roughly 80-85% of tenders for allopurinol, its first own-label product in Europe.
- Emerging markets run on brand promotion - 80% of emerging-market revenue comes from brand promotion across French West Africa, Kenya, Sri Lanka, and Myanmar, supported by over 790 product registrations and a licensing partnership with Aspen that covers 30 African countries.
- Regulatory overhang - the Goa sterile plant received a USFDA warning letter, though two of four lines have been cleared to resume supply; the company is executing a master manufacturing efficiency plan that already delivered a 26% sequential jump in international formulations in the first quarter of FY26.
3. Over-the-counter and oral care: a small consumer bet built on a prescription legacy
Through its wholly owned subsidiary Warren Remedies, Indoco sells sensitivity toothpaste and oral care products almost entirely through chemists, with a new dedicated factory that began production in 2024.
- Ethical roots, consumer ambitions - the OTC business was carved out to take products that had long been prescribed by doctors-like Sensodent K toothpaste-directly to consumers, though 99% of sales still flow through the chemist channel rather than grocers or modern trade.
- A factory built for efficiency - the Warren Remedies plant in Aurangabad can make 5,000-kilogram toothpaste batches with only five people, and as of mid-2026 had begun exporting toothpaste to South Africa, though it does not yet hold a regulated-market approval.
- Small but in a large market - the sensitivity toothpaste market in India is roughly ₹1,100 crore, and Indoco is working to expand beyond chemists into quick-commerce and modern trade, where its presence is currently negligible compared to competitors like Sensodyne.
Manufacturing and R&D backbone
Eleven manufacturing plants and a 1,00,000-square-foot R&D centre with over 300 scientists supply every part of the business, with a growing emphasis on automation, energy efficiency, and complex dosage forms.
- Regulatory-grade infrastructure - the six finished-dosage and four API plants are approved by the USFDA, UK-MHRA, and Australia’s TGA, and all facilities operate under WHO good manufacturing practices.
- Complex dosage forms in-house - the R&D centre develops sterile ophthalmic emulsions, nano-suspensions, depot-based long-acting injectables, and novel drug delivery systems; a microparticulate oral suspension technology and a geometrically diluted granulation process for glimepiride are two recent in-house innovations that cut processing time from 36 hours to 14.
- Backward integration into APIs - the Patalganga API plant can produce 25 tons of allopurinol a month, and the majority of Indoco’s ANDA filings are backed by APIs made in its own facilities, securing supply and controlling cost.
- Energy and carbon cuts - open-access solar at Patalganga and the Rabale R&D centre cuts carbon emissions by 335 tons of CO₂ per month; briquettes replaced fossil fuel at the Waluj plant, and the plants use treated effluent, recycling roughly 50 to 60 kiloliters of treated effluent daily.
Group structure and partners
Indoco Remedies is the listed parent, with subsidiaries that extend its reach into oral care manufacturing, US distribution, and UK marketing, plus two solar-power associates that supply captive green electricity.
- Warren Remedies Private Limited - a wholly owned subsidiary that operates the Aurangabad oral care and API intermediate plant; Indoco provides brand licences, technology transfer, and corporate guarantees to the subsidiary, and its sales are consolidated into the domestic stomatologicals segment.
- Florida Pharmaceutical Products (FPP) - an 85%-owned step-down subsidiary acquired in 2023 for USD 4 million that distributes and markets generic pharmaceuticals in the US, giving Indoco a direct commercial presence in that market.
- Indoco Remedies UK Limited - a subsidiary that launched Ticagrelor tablets in the UK in mid-2025 through the distributor Clarity Pharma, with plans for around 20 products over 18 months.
- Solar captive associates - Indoco holds 26% stakes in Jalansar Wind Energy and Kanakal Wind Energy, special-purpose vehicles building solar plants in Solapur, Maharashtra, whose power will be supplied exclusively to Indoco under India’s captive-user electricity rules.
- Ophthalmic divestiture - the India and Africa ophthalmic business was sold to Sunways in May 2026 for ₹110 crore, allowing Indoco to concentrate on its core therapeutic areas while the brands receive dedicated attention under their new owner.